SPOTLIGHT -
Nestlyy} SA might sell 25% ofAlcon if it decides to do a partial initial public offering of the unitnext year, according to CEO Peter Brabeck-Letmathe.
Patients with dry eye suffer from worse sleep quality
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ophthalmologists embrace potential of clinically tested nutraceuticals for dry eye disease
EyePod: Modifier Gene Therapy: What is it?
Pantheon Vision holds two pre-submission meetings with FDA
The role of multimodal imaging in ocular trauma